Match!
David Faleck
Icahn School of Medicine at Mount Sinai
35Publications
5H-index
106Citations
Publications 35
Newest
#1David Faleck (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
#2Adam Winters (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
Last.Ryan C. Ungaro (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 11
view all 34 authors...
Background & Aims Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. Methods We analyzed data from a retrospective, multicenter, consortium...
3 CitationsSource
#1Jenna L. Koliani-Pace (Dartmouth–Hitchcock Medical Center)H-Index: 5
#2Siddharth Singh (UCSD: University of California, San Diego)H-Index: 39
Last.Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
view all 35 authors...
Source
Source
Source
#1Joseph Meserve (UCSD: University of California, San Diego)H-Index: 6
#2Satimai Aniwan (Mayo Clinic)H-Index: 6
Last.Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
view all 33 authors...
Background & Aims There are few real-world data on the safety of vedolizumab for treatment of Crohn’s disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. Methods We performed a retrospective review of data from a multicenter consortium database (from May 2014 through June 2017). Infectious and non-infectious adverse events were defined as those requiring antibiotics, h...
7 CitationsSource
#1Matthew C. Choy (University of Melbourne)H-Index: 4
#2Dean Seah (Austin Hospital)H-Index: 3
Last.Peter De Cruz (University of Melbourne)H-Index: 18
view all 13 authors...
Background: Infliximab is an effective salvage therapy in acute severe ulcerative colitis; however, the optimal dosing strategy is unknown. We performed a systematic review and meta-analysis to examine the impact of infliximab dosage and intensification on colectomy-free survival in acute severe ulcerative colitis. Methods: Studies reporting outcomes of hospitalized steroid-refractory acute severe ulcerative colitis treated with infliximab salvage were identified. Infliximab use was categorized ...
5 CitationsSource
#1Tomer AdarH-Index: 13
#2David FaleckH-Index: 5
view all 12 authors...
Source
#1Stacy TseH-Index: 1
#2Bruce E. SandsH-Index: 70
Last.Marla DubinskyH-Index: 59
view all 12 authors...
Source
#1Parambir S. DulaiH-Index: 20
#2Siddharth SinghH-Index: 39
Last.Charlie CaoH-Index: 3
view all 40 authors...
Source
#1David FaleckH-Index: 5
#2Eugenia ShmidtH-Index: 9
Last.Jean-Frederic ColombelH-Index: 129
view all 8 authors...
Source
1234